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Abstract
Background: The purpose of this study is to analyze the anatomic distribution, clinical features, therapeutic methods,
and prognosis factors of primary gastrointestinal lymphoma (PGIL).
Methods: Clinical data of 87 cases PGIL in the First Affiliated Hospital of Dalian Medical University from January 1999 to
December 2010 were collected. Follow-ups were made according to the clinical feature, pathological pattern, clinical
stage, and therapeutic method. Kapan Meier method was used for the survival analysis. Log-rank test was used to
perform univariate survival analysis. COX multivariate analysis was carried out to analyze factors of P < 0.05 in univariate
survival analysis.
Results: The incidence of PGIL significantly increased in patients more than 40 years old (87.4 %). Clinical symptoms of
PGIL were indistinguishable from other digestive system diseases, which included abdominal pain or discomfort
(72.4 %), lack of appetite (16.3 %), gastrointestinal hemorrhage (14.9 %), and diarrhea (12.8 %). Some patients
presented with systemic symptoms or complications, such as weight loss (35.6 %) and digestive tract obstruction
(13.8 %). Primary gastric lymphoma (PGL) was the most common, followed by primary intestine lymphoma (PIL).
The majority of PGIL were single lesion, which included 40 cases (87 %) PGL and 35 cases (94.5 %) PIL. The most
frequent site of PGL was antrum of the stomach (43.5 %), as to PIL, the small intestine (90.2 %) was the most
frequent site, especially within 100 cm far away from ileocecal valve. Most of PGIL were derived from B cell (93.1 %).
The most common pathological type was mucosa-associated lymphoid tissue (MALT) (67.4 %) in the PGL group and
diffuse large B cell lymphoma (DLBCL) (46.3 %) in the PIL group. Surgical treatment had been performed in most of
PGIL, which included 32 cases in the PGL group and 38 cases in the PIL group. The 1-year overall survival (OS) and the
3-year OS were 82 and 77 %, respectively. Analysis of single factor affecting prognosis showed that lesion location,
sources of cells, and clinical stage were associated with OS. PGL group had better OS than that of PIL group (1-year 89
vs 62 %, 3-year 84 vs 50 %, P = 0.03). B cell-originated group had better OS than that of T cell-originated group (1-year
89 vs 36 %, 3-year 85 vs 0 %, P = 0.008). Stage I + II group had better OS than that of stage III + IV group (1-year 89 vs
38 %, 3-year 87 vs 0 %, P = 0.007). Multivariate analysis showed that clinical stage and sources of cells were the significant
independent prognostic factors.
Conclusions: It was more common to find location of PGIL in the stomach than that in the intestine. The most common
pathological type was MALT in the PGL and DLBCL in the PIL. The treatment of PGL was focused on chemotherapy. It
was noting that since PIL was not only difficult to make confirmed diagnosis but also likely to develop with
complications, so it was usually needed surgical excision. Clinical stage and pathological pattern were related to
prognosis of PGIL.
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Background
Deriving from lymphoid tissue beneath mucosa of gastro-
intestinal wall, primary gastrointestinal lymphoma (PGIL)
was extranodal non-Hodgkin’s lymphomas (NHL) that ac-
count for 24–49 % of NHL [1]. It used to appear in the
stomach and small intestines, accounting for 1–4 % of
gastroenteric tumor [2]. PGIL was difficult to identify be-
cause clinical features of PGIL was indistinguishable from
other gastroenteric diseases, especially from gastrointes-
tinal tumor, which attributes to a high misdiagnosis rate in
clinical practice. Besides, the treatment methods were quite
different from each other. A retrospective analysis was
made on 87 PGIL patients from January 1999 to December
2010 in the First Affiliated Hospital of Dalian Medical
University; we summarized their clinical features, patho-
logical patterns, treatment methods, and prognosis factors.
Methods
1. Patients: clinical data of 87 PGIL patients from
January 1999 to December 2010 in the First Affiliated
Hospital of Dalian Medical University were collected.
2. Diagnosis and stages standards: all patients were
diagnosed according to the Dawson standard of
gastrointestinal lymphoma, which included (1)
absence of perpheral lymphadenopathy at the time
of presentation; (2) lack of enlarged mediastinal
lymph nodes; (3) normal total and differential white
blood cell count; (4) predominance of bowel lesion
at the time of laparotomy with only lymph nodes
obviously affected in the immediate vicinity; and (5)
no lymphomatous involvement of liver and spleen.
Clinical stages were established according to Ann
Arbor staging with Musshoff modification. Stage I:
lesions are confined to the gastrointestinal tract,
under the side of the diaphragm, without lymph
node metastasis. Stage II: lesions invade from the
gastrointestinal tract to abdominal cavity, with
peritoneal lymph node involvement. Stage III:
lesions are confined to the gastrointestinal tract,
with lymph node metastasis on both sides of the
diaphragm. Stage IV: huge tumor with or without
lymph node metastasis, and diffuse non-gastrointestinal
tract organs or tissues are involved.
Pathological diagnosis was referred to the
classification of lymphoma by the World Health
Organization (WHO). The main pathological
patterns of primary gastrointestinal lymphoma are
(1) B cell mucosa-associated lymphoid tissue
(MALT); (2) diffuse large B cell lymphoma (DLBCL);
(3) mantle cell lymphoma (MCL); and (4)
enteropathy-associated T cell lymphoma (EATL).
3. Treatment: 87 patients were divided into operation
group and non-operation group. Operation group
included surgery alone and surgery combined with
postoperative chemotherapy or other treatment. All
chemotherapy plans were CHOP plan (phosphoric
acid amide + doxorubicin + vincristine + prednisone).
Rituximab was used in biotherapy.
4. Follow-up: 64 patients finished follow-up visit by phone
until December 2013, and the rate of follow-up was
73.6 %. Follow-up information was obtained through
follow-up ambulatory visits and phone contacts with
patients or their family members. Survival time was
measured from the date of diagnosis to death from any
cause or to the last follow-up.
5. Statistical approaches: we used SPSS 21.0 software
to analyze data. Kapan Meier method was used for
the survival analysis. Log-rank test was used to perform
univariate survival analysis. COX multivariate analysis
was carried out to analyze factors of P < 0.05 in
univariate survival analysis. P < 0.05 was considered to
indicate statistically significant.
6. Ethics statement: this study was approved by the
Ethical Committee of First Affiliated Hospital of
Dalian Medical University, and the reference
number was LCKY2013-46.
Results
1. General information: there were 45 males and 42
females in 87 PGIL patients with the male-to-female
ratio of 1.07:1. The average age was 57.3 years old,
ranged from 15 to 87 years old. Most of patients
were older than 40 years old (n = 76, 87.4 %); only
11 patients were younger than 40 years old (12.6 %).
Symptoms of PGIL were unspecific. The main
gastrointestinal symptoms included abdominal pain
or discomfort (n = 63, 72.4 %), lack of appetite (n = 14,
16.3 %), gastrointestinal hemorrhage (n = 13, 14.9 %),
and diarrhea (n = 11, 12.8 %). Some patients presented
with systemic symptoms or complications, such as
weight loss (n = 31, 35.6 %), digestive tract obstruction
(n = 12, 13.8 %), and perforation (n = 6, 6.8 %).
2. Lesion locations (Table 1): 87 patients included 46
cases primary gastric lymphoma, 37 cases primary
small intestinal lymphomas, and 4 cases primary
colon lymphoma. The majority of PGIL were
single lesion, which included 40 cases (87 %)
primary gastric lymphoma (PGL) and 35 cases
(94.5 %) PIL. As shown in Table 1, the majority of
PGL were located at the antrum of the stomach
(n = 20, 43.5 %), followed by the body of the
stomach (n = 16, 34.8 %). The most frequent site
of PIL was the small intestine (n = 37, 90.2 %),
which mostly were located at the ileum (n = 26,
70.3 %), especially within 100 cm far away from
ileocecal valve (n = 25).
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3. Pathologic features and stages (Table 2): all patients
were non-Hodgkin’s lymphoma, and most of cases
were derived from B cell (n = 64). In the PGL group,
the most common type was MALT (n = 31),
followed by DLBCL (n = 14). In the PIL group, the
most common type was DLBCL (n = 19), followed
by MALT (n = 10), and fewer were EATL (n = 6).
The patients belonged to stage I E 46 cases, stage II
E 31 cases, stage III 4 cases, and stage IV 6 cases.
4. Treatment (Table 3):
As for 46 patients in PGL group, (1) 32 patients
accepted surgical treatment, including radical
operation (n = 27) and palliative surgery (n = 5).
Radical operation included total gastrectomy (n = 6),
radical proximal gastrectomy (n = 4,) and radical
distal gastrectomy (n = 17). Eighteen patients
accepted surgery alone, and 10 patients were
treated with CHOP after surgery, while 4 patients
were treated with R-CHOP (rituximab + phosphoric
acid amide + doxorubicin + vincristine + prednisone).
(2) Thirteen patients with PGL accepted non-operation
treatment, including 7 patients treated with CHOP, 3
patients treated with R-CHOP, and 2 patients accepted
anti-HP treatment alone. Rituximab alone was used to
treat only 1 patient. (3) One patient abandoned
treatment after confirmed diagnosis.
As for 41 patients in PIL group, (1) 38 patients
accepted surgical treatment, including 27 patients
with radical right hemicolectomy, 16 patients with
small bowel resection, and 7 patients with palliative
surgery. Seventeen patients accepted surgery alone,
and 17 patients were treated with CHOP after surgery,
while 4 patients were treated with surgery and
rituximab. (2) Two patients accepted non-operation
treatment by R-CHOP plan. (3) One patient abandoned
treatment after confirmed diagnosis.
5. Follow-up: 64 patients with follow-up information
were taken into the survial analysis. The 1-year OS
and the 3-year OS were 82 and 77 %, respectively.
By univariate analysis, we found that lesion locations,
sources of cells, and clinical stage were associated with
OS, but surgery did not prolong the survival rate of
PGIL compared with other treatments. PGL group had
better OS than that of PIL group (1-year 89 vs 62 %,
3-year 84 vs 50 %, P = 0.03) (Fig. 1). B cell-originated
group had better OS than that of T cell-originated
group (1-year 89 vs 36 %, 3-year 85 vs 0 %, P = 0.008)
(Fig. 2). There was no significant difference of the
1-year and 3-year OS between stage I and stage II,
stage III and stage IV patients (data not shown).
But stage I + II group had better OS than that of
Table 1 Lesion location distribution of 87 patients with PGIL
Lesion location Case number Proportion (%)
Stomach 46 52.9
Antrum of stomach 20 43.5
Body of stomach 16 34.8
Fundus of stomach 3 6.5
Cardia of stomach 1 2.2
Multiple locations 6 13.0




Multiple locations 2 5.4
Colon 4 4.6
Total 87 100
Table 2 Pathological patterns of 87 patients with PGIL
Location Pathological pattern (case number)
MALT DLBCL EATL unclassed
Stomach 31 14 0 1
Intestines 10 19 6 6
Table 3 Treatment plan of 87 patients with PGIL



































*Two patients abandoned treatment
Ge et al. World Journal of Surgical Oncology  (2016) 14:85 Page 3 of 7
stage III + IV group (1-year 89 vs 38 %,
3-year 87 vs 0 %, P = 0.007) (Fig. 3). Multivariate
analysis showed that clinical stage and sources of
cells were the significant independent prognostic
factors (Table 4).
Discussion
Although PGIL pathogenesis remained unknown, certain
factors had been considered to be related with its inci-
dence for a long time, including virus infection, auto-
immune deficiency, and environment pollution. [3, 4].
The incidence of PGIL had increased in Asia, North
America, and Europe [5–8]. Many studies showed that
the stomach was the most commonly involved site
followed by the intestine, while in Pacific Ocean, small
intestines were mostly seen followed by the stomach and
colon [9, 10]. In our study, we found that 53.9 % patients
were PGL and 46.1 % were PIL. Furthermore, the major-
ity of PGL were located at the antrum of the stomach,
followed by the body of the stomach, and the most fre-
quent site of PIL was the small intestine, especially
within 100 cm far away from ileocecal valve. Besides, it
should be noticed in clinical work that there might be
multiple lesion locations in PGIL.
Fig. 1 Survival curves of 64 patients with PGIL according to different lesion locations. All 64 patients with PGIL were divided into two groups: PGL group
and PIL group, according to different lesion locations. PGL group had better OS than that of PIL group (1-year 89 vs 62 %, 3-year 84 vs 50 %, P= 0.03)
Fig. 2 Survival curves of 62 patients with PGIL according to different sources of cells. All 62 patients with PGIL were divided into two groups: source of
T cell and source of B cell. B cell-originated group had better OS than that of T cell-originated group (1-year 89 vs 36 %, 3-year 85 vs 0 %, P = 0.008)
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Clinical symptoms of PGIL were indistinguishable
from other digestive system diseases. The main symptom
included abdominal pain or discomfort, together with
weight loss and nausea and other intestinal symptoms
[11, 12]. Imageological examination might show wall
thickened and intestinal masses; it was usually difficult
to identify from other gastrointestinal cancer. Endoscopy
and biopsy were the most reliable methods for confirm-
ing diagnosis [13, 14].
The surgical treatment was traditionally considered
as the main treatment methods of PGIL. Most of pa-
tients accepted the radical resection. Palliative resec-
tion might due to huge size of tumor or extensive
transfer of lymph node. However, as lymphoma was
highly sensitive to chemotherapy, the main treatment
of PGIL was non-surgery now. A prospective study
showed that surgery treatment could not improve the
10-year survival rate of PGIL by comparing of surgery
plus chemotherapy with chemotherapy alone [6]. Re-
cently, there was a study showed that it had equivalent
efficacy whether patients accepted operation or not
[11]. Moreover, more and more studies demonstrated
that non-surgery strategies had better OS [15, 16]. In
our study, 50 patients accepted non-surgery methods,
such as CHOP or R-CHOP, which account for 54.5 %
of total patients. Rituximab is a chimeric monoclonal
antibody against the protein CD20, which is primarily
found on the surface of immune system B cells. Rituxi-
mab destroys both normal and malignant B cells that
have CD20 on their surfaces. The addition of rituxi-
mab has improved the overall survival of lymphoma.
Many studies have showed that rituximab can improve
the efficacy of chemotherapy after relapse [17, 18]. In
our retrospective study, there were not all patients
whose CD20-positive approved rituximab therapy due
to economic reasons. Nowadays, surgery had gradually
been replaced by non-surgery treatment. However,
many studies showed that surgery was benefit to pa-
tients who present with hemorrhage, perforation, or
ileus [19, 20], especially to PIL patients. PIL was not
only difficult to make confirmed diagnosis but also
likely to develop with complications, so it was usually
needed surgical excision and then diagnosed by
pathologic analysis. In our study, there were 41 PIL
patients, which 38 patients accepted surgical treat-
ment. We believed that surgery was the main treat-
ment method of undetermined diagnosis of PGIL
patients, with its irreplaceable advantages as follows:
(1) surgery was an important means to gain the
pathological diagnosis and determine diagnosis; (2)
postoperative specimens could be graded and staged
correctly in order to judge prognosis more exactly;
(3) surgery might alleviate tumor load, relieve clinical
symptoms, and strengthen effect of other treatment,
such as postoperative chemotherapy; and (4) patients
who were insensitive to other treatment or appeared
life-threatening complications should choose surgery
as soon as possible.
In summary, the reasonable clinical treatment method
of PGIL should be made according to the location, clin-
ical stage, pathologic pattern, and with complications
or not.
Fig. 3 Survival curves of 64 patients with PGIL according to different clinical stages. Stage I + II group had better OS than that of stage III + IV group
(1-year 89 vs 38 %, 3-year 87 vs 0 %, P = 0.007)
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Conclusions
In conclusion, our study showed that it was more com-
mon to find location of PGIL in the stomach than that
in the intestine. The most common pathological type
was MALT in the PGL group and DLBCL in the PIL
group. The treatment of PGL was focused on chemo-
therapy. It was noting that since PIL was not only diffi-
cult to make confirmed diagnosis but also likely to
develop with complications, so it was usually needed
surgical excision and then diagnosed by pathologic ana-
lysis. Clinical stage and pathological pattern were re-
lated to prognosis of PGIL.
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Univariate analysis Multivariate analysis
OS P value HR P value
1 year 3 year
Gender
Male 31 79.4 79 75 0.564
Female 33 89.4 85 79
Age
<60 years 37 87.5 83 80 0.216
≥60 years 27 77.9 80 71
Location
Stomach 45 96.5 89 84 0.03 Not significant
Intestines 19 34.9 62 50
Size
<5 cm 34 97.3 82 79 0.142
≥5 cm 30 70.8 82 74
Clinical stages
I + II 55 95.5 89 87 0.003 2.576 (1.024 3.809) 0.001
III + IV 9 20.0 38 0
Source of cells
Source of B cells 57 94.7 89 85 0.006 3.119 (1.524 6.384) 0.002
MALT 35 100.9 94 91
DLBCL 22 85.0 81 74
Source of T cells 5 14.6 36 0
EATL 5 14.6 36 0
Treatment methods
Surgery alone 22 80.9 81 72 0.604
Surgery combined other treatment 27 90.5 88 83
Non-operation 15 49.1 73 73
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